期刊
VACCINE
卷 27, 期 9, 页码 1365-1376出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2008.12.044
关键词
Amyloid; Oligomer; Epitope
资金
- Canadian Institutes of Health Research
- Natural Science and Engineering Research Council of Canada
- Ontario Alzheimer's Society
Immunization with amyloid-beta (A beta) peptide reduces amyloid load in animal studies and in humans; however clinical trials resulted in the development of a pro-inflammatory cellular response to A beta. Apoptosis has been employed to stimulate humoral and Th2-biased cellular immune responses. Thus, we sought to investigate whether immunization using a DNA vaccine encoding A beta in conjunction with an attenuated caspase generates therapeutically effective antibodies. Plasmids encoding A beta and an attenuated caspase were less effective in reducing amyloid pathology than those encoding A beta alone. Moreover, use of A beta with an Arctic mutation (E22G) as an immunogen was less effective than wild-type A beta in terms of improvements in pathology. Low levels of IgG and IgM were generated in response to immunization with a plasmid encoding wild-type A beta. These antibodies decreased plaque load by as much as 36 +/- 8% and insoluble A beta 42 levels by 56 +/- 3%. Clearance of A beta was most effective when antibodies were directed against N-terminal epitopes of A beta. Moreover, immunization reduced CAA by as much as 69 +/- 12% in TgCRND8 mice. Finally, high-molecular-weight oligomers and A beta trimers were significantly reduced with immunization. Thus, immunization with a plasmid encoding A beta alone drives an attenuated immune response that is sufficient to clear amyloid pathology in a mouse model of Alzheimer's disease. (C) 2009 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据